Evaxion Biotech A/S - ADR EVAX

NAS: EVAX | ISIN: US29970R1059 19/12/2025

4,700 USD (-18,26%)

(-18,26%) 19/12/2025

Grafiek Evaxion Biotech A/S - ADR

Grafiek Evaxion Biotech A/S - ADR

1 dag1d -18,26%
1 week1w -18,69%
1 maand1m -9,27%
3 maanden3m 54,10%
6 maanden6m 92,62%
1 jaar1j 417,79%
5 jaar5j -52,48%

Evaxion Biotech A/S - ADR in het nieuws

Toon enkel gratis nieuws

19 december 2025 · Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2 · Persbericht

6 december 2025 · Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting · Persbericht

20 november 2025 · Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1 · Persbericht

12 november 2025 · Evaxion announce 2026 financial calendar · Persbericht

7 november 2025 · Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 · Persbericht

6 november 2025 · Evaxion announces business update and third quarter 2025 financial results · Persbericht

3 november 2025 · Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate · Persbericht

31 oktober 2025 · Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 · Persbericht

31 oktober 2025 · Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 · Persbericht

30 oktober 2025 · Evaxion raises $7.2 million, extending cash runway to second half of 2027 · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe